Compare ESOA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESOA | CGEN |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.2M | 143.1M |
| IPO Year | 2006 | 2000 |
| Metric | ESOA | CGEN |
|---|---|---|
| Price | $8.46 | $1.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $21.00 | $4.00 |
| AVG Volume (30 Days) | 167.6K | ★ 538.0K |
| Earning Date | 02-09-2026 | 03-03-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $411,001,373.00 | $6,903,000.00 |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $5.24 | $231.15 |
| P/E Ratio | $413.00 | ★ N/A |
| Revenue Growth | ★ 16.80 | N/A |
| 52 Week Low | $7.64 | $1.13 |
| 52 Week High | $15.23 | $2.66 |
| Indicator | ESOA | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 71.41 |
| Support Level | $8.07 | $1.43 |
| Resistance Level | $8.52 | $2.01 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 81.67 | 94.83 |
Energy Services of America Corporation is engaged in providing contracting services for energy-related companies. The company is predominantly engaged in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It services the gas, petroleum, power, chemical, and automotive industries and does incidental work such as water and sewer projects. Energy Service's other services include liquid pipeline construction, pump station construction, production facility construction, water and sewer pipeline installations, various maintenance and repair services, and other services related to pipeline construction.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.